Clinical Trials For Tinnitus Treatments – Tinnitus is a condition that affects 10% to 20% of the population in the United States. It is characterized by sounds in the ears or ears that are not related to external noise and are sometimes called phantom sounds or tinnitus.

Recently, Dr. Thanos Tzounopoulos, professor emeritus, vice chair of research in the Department of Otolaryngology at the University of Pittsburgh and director of the Pittsburgh Hearing Research Center, was able to determine that the source of tinnitus is in the brain, not the ear. This has helped to find ways to diagnose and find a cure for this disease.

Clinical Trials For Tinnitus Treatments

The tinnitus treatment program at the UPMC Audiology Center recommends a clinical and hearing evaluation as the first step in treatment. This may include a full body exam, an ear, nose and throat exam, and a review of your medical history.

Different Bimodal Neuromodulation Settings Reduce Tinnitus Symptoms In A Large Randomized Trial

An audiologist may also perform a number of tests to provide information about tinnitus, hearing and hearing loss, which may include:

Typically, treatment plans, such as those offered by UPMC’s Tinnitus Treatment Program, include a combination of education/counseling and the use of low-frequency sounds provided by noise-making devices, hearing aids, or environmental sounds. This treatment is aimed at helping people deal with their tinnitus symptoms. It is not a drug or medicine.

Dr. Thanos Tzounopoulos, director of the Pittsburgh Hearing Research Center, was able to determine that the source of tinnitus is in the brain, not the ear. In 2013, Dr. Tzounopoulos discovered a molecular target for tinnitus: the dysfunctional potassium channel. In collaboration with the medical expert Dr. For Peter Wipf, the team of Dr. Tzounopoulousa modified an existing drug, a potassium channel blocker, to create a drug that could reduce or eliminate phantom sounds.

Tinnitus Treatment Report

After many years of refining the drug to adapt to other potassium channels associated with tinnitus and reduce its effects, the drug is now being tested to determine the safety of human trials where a new research project will be provided and clinical trials will begin.

For the latest news on the latest research, subscribe to EEF’s monthly newsletter. How can I find a doctor?

For proper care, it is recommended that you visit an audiologist. If you live in the Pittsburgh area or western Pennsylvania, you may want to consider the tinnitus treatment program at UPMC Audiology Center. Otherwise, ask for a referral to your general practitioner or use the doctor finder tool provided by your insurance company.

Treating Tinnitus Through The…tongue?

Have a question about tinnitus for a University of Pittsburgh scientist? Send your Eye & Ear Foundation question to askthescientist@ and we’ll do our best to answer it.

In order to support the original research of Dr. Tzounopoulos for tinnitus treatment, make a donation to the Eye & Ear Foundation. Neuromod Devices Limited (“Neuromod”), an Irish medical company specializing in the treatment of chronic tinnitus, has announced the release of results. a TENT A1 clinical trial (Evaluation of Neuromodulation Treatment for Tinnitus) v

In a paper titled: “Bimodal Neuromodulation Combining Sound and Tongue Stimulation Reduces Tinnitus Symptoms in a Large Randomized Clinical Study.”

Pdf] Toward A Global Consensus On Outcome Measures For Clinical Trials In Tinnitus: Report From The First International Meeting Of The Comit Initiative, November 14, 2014, Amsterdam, The Netherlands

The clinical trial was conducted between 2016 and 2019 and was designed to monitor changes in the severity of tinnitus symptoms. The trial investigated bimodal neuromodulation using the non-invasive Neuromod device, which delivers sound to the ears and electrical stimulation to the tongue.

According to Neuromod, “this study represents the largest and longest follow-up trial in the field of tinnitus” with 326 people, which provides evidence of the safety, efficacy and tolerance of bimodal neuromodulation in the treatment of tinnitus patients. Eighty-six of the participants who followed the treatment reported an improvement in tinnitus symptoms when tested after 12 weeks of treatment, with the majority achieving sustained benefits 12 months after treatment, according to the company.

The study was conducted at the Wellcome Trust-HRB Clinical Research Facility, St James’s Hospital, Dublin, Ireland and the Tinnituszentrum of the University of Regensburg, Germany. There were stable therapeutic results in all clinical settings, without serious adverse events (treatment-related SAEs with a high rate among the main group of participants, according to Neuromod). The National Medical Research Organization (NAMSA, Minneapolis, Minnesota) led and supported the completion of clinical trials of Neuromod.

Study Shows Promising Treatment For Tinnitus

The tinnitus device, now called Lenire, used in this study was developed by Neuromod and consists of wireless headphones (Bluetooth) that transmit sound to both ears, combined with electrical pulses, which are delivered to 32 electrodes. on. tip of the tongue using a Tonguetip device. Time, force, and stimulus delivery are controlled by a hand controller, which each participant is trained to use. Before using the drug, the device is set according to the patient’s hearing history and is optimized according to the level of the patient’s tongue stimulation.

During the trial, participants were instructed to use the Leniredevice for 60 minutes a day for 12 weeks. Of the 326 people who registered, 83.7% used the device for at least 36 hours during the 12-week treatment period. The company reported that at the end of the period, the participants experienced a significant reduction in tinnitus symptom severity.

After treatment was completed, participants returned their device and were evaluated at three consecutive visits for up to 12 months. Sixty-seven percent of those who completed the study (n = 272) confirmed that they had benefited from using the device, and 77.8% (n = 270) said they would recommend the treatment to other tinnitus sufferers.

Specialised Treatment Based On Cognitive Behaviour Therapy Versus Usual Care For Tinnitus: A Randomised Controlled Trial

Study participants were screened and selected according to a pre-defined list of inclusion and exclusion criteria to ensure that the trial included a large sample of people with tinnitus. Information about these methods is available at https://www.clinicaltrials.gov/ using the identifier NCT02669069, and the full document can be found here: https://www.neuromoddevices.com/tenta1results.

Dr. Ross O’Neill, CEO of Neuromod, said: “We are delighted to announce the positive results of our TENT-A1 trial, which showed a significant improvement in tinnitus symptoms in patients using our Lenire device. There is a need for global recognition. for evidence-based treatments such as Lenire due to the lack of effective treatment options for these debilitating conditions.Neuromod is proud to be at the forefront of research and development of new treatments that can help combat this condition that affects 10-15% of the world’s population.

Hubert Lim, Neuromod’s Chief Scientific Officer, said: “I am very proud that our company has been able to conduct such a randomized clinical trial in two countries involving 326 people to demonstrate the safety and efficacy of a new tinnitus treatment.” This study followed the results of the treatment for 12 months after treatment, the first in the field of tinnitus to test the long-term effects of the treatment method. The results are very exciting and I hope to continue our work to develop a bimodal neuromodulation treatment that will help as many people with tinnitus as possible. “

Could A Clinical Trial For Tinnitus Treatment Shed Light On Covid?

Original article: Conlon B, Langguth B, Hamilton C, et al. Bimodal neuromodulation combining sound and tongue stimulation reduces tinnitus symptoms in a large randomized clinical trial. Lenira’s new study, “TENT-A3,” is part of a follow-up study on the Lenira bimodal neuromodulation device and will evaluate the safety and efficacy of Lenira for the treatment of chronic, refractory symptoms.

) was submitted to ClinicalTrials.gov on January 26, 2022 and published publicly for the first time today (February 7, 2022).

Interesting, but note: “Level 3” is not the same as “Phase 3” and the TENT-A3 is considered a “Phase N/A” (test device without phase)

A Clinical Trial Of A Patient Customized Virtual Reality Intervention For Tinnitus

Start date February 1, 2022. As of today (February 7, 2022), this study has not begun recruiting participants. However, the current situation

It can change to “Recruitment” every day. (Meanwhile, we can also see the official announcement from Neuromod/Lenira.) Speaking of recruiting… the research write-up seems to give us an idea of where the research will take place (recruitment location), which includes

Three of the following four countries: Ireland, Belgium, Netherlands, Germany. (The “three out of four countries” phenomenon is due to the fact that the study profile mentions “three study areas”…while recruiting participants in four countries. This detail becomes clear as soon as the study is set to Recruiting. )

Chronic Tinnitus: Diagnosis And Treatment (01.04.2022)

TENT-A3 is a prospective, single-arm, replication study evaluating the safety and efficacy of the Lenire device in the treatment of tinnitus. The Lenire device provides bimodal stimulation (noise and tongue) to relieve chronic, persistent tinnitus symptoms. Students attending one of the three study centers with chronic tinnitus and meeting the inclusion criteria are included in the study while the study center is active.

The purpose of TENT-A3 is to determine whether the addition of tongue stimulation to sound stimulation alone provides additional clinical benefits in tinnitus symptoms over the auditory stimulation component of bimodal treatment.

The purpose of this

Low Level Laser Therapy Effective For Tinnitus Treatment

Recruiting for clinical trials, clinical trials for tinnitus, clinical trials for copd, clinical trials for emphysema treatments, clinical trials for psoriasis, tinnitus clinical trials canada, clinical trials for cll, clinical trials for eczema, clinical trials for vitiligo, software for clinical trials, clinical trials for mds, sops for clinical trials